Literature DB >> 9351622

Lower airway inflammation in infants and young children with cystic fibrosis.

D S Armstrong1, K Grimwood, J B Carlin, R Carzino, J P Gutièrrez, J Hull, A Olinsky, E M Phelan, C F Robertson, P D Phelan.   

Abstract

Airway inflammation is an important component of cystic fibrosis (CF) lung disease. To determine whether this begins early in the illness, before the onset of infection, we examined bronchoalveolar lavage (BAL) fluid from 46 newly diagnosed infants with CF under the age of 6 mo identified by a neonatal screening program. These infants were divided into three groups: 10 had not experienced respiratory symptoms or received antibiotics and pathogens were absent in their BAL fluid; 18 had clear evidence of lower respiratory viral or bacterial (> or = 10(5) CFU/ml) infection; and the remaining 18 had either respiratory symptoms, taken antibiotics, or had < 10(5) CFU/ml of respiratory pathogens. Their BAL cytology, interleukin-8, and elastolytic activity were compared with those from 13 control subjects. In a longitudinal study to assess if inflammation develops or persists in the absence of infection, the results of 56 paired annual BAL specimens from 44 CF infants were grouped according to whether they showed absence, development, clearance, or persistence of infection. In newly diagnosed infants with CF, those without infection had BAL profiles comparable with control subjects while those with a lower respiratory infection had evidence of airway inflammation. In older children, the development and persistence of infection was accompanied by increased inflammatory markers, whereas these were decreased in the absence, or with the clearance, of infection. We conclude that airway inflammation follows respiratory infection and, in young children, improves when pathogens are eradicated from the airways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351622     DOI: 10.1164/ajrccm.156.4.96-11058

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  104 in total

Review 1.  Macrolides in the respiratory tract in cystic fibrosis.

Authors:  Adam Jaffé; Mark Rosenthal
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Repurposing tromethamine as inhaled therapy to treat CF airway disease.

Authors:  Mahmoud H Abou Alaiwa; Janice L Launspach; Kelsey A Sheets; Jade A Rivera; Nicholas D Gansemer; Peter J Taft; Peter S Thorne; Michael J Welsh; David A Stoltz; Joseph Zabner
Journal:  JCI Insight       Date:  2016-06-02

3.  Binding of Pseudomonas aeruginosa AlgZ to sites upstream of the algZ promoter leads to repression of transcription.

Authors:  Deborah M Ramsey; Patricia J Baynham; Daniel J Wozniak
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

4.  Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8.

Authors:  Sharmistha Bhattacharyya; Nagaraja S Balakathiresan; Clifton Dalgard; Usha Gutti; David Armistead; Cathy Jozwik; Meera Srivastava; Harvey B Pollard; Roopa Biswas
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

5.  Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

Authors:  Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

Review 6.  Is bronchoscopy an obsolete tool in cystic fibrosis? The role of bronchoscopy in cystic fibrosis and its clinical use.

Authors:  Lisa Paul
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 7.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 8.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 9.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  Early airway infection, inflammation, and lung function in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood; Claire Wainwright
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.